P2RY12 and coronary artery disorder: In a clinical scenario, the use of subcutaneous selatogrel in 345 patients with stable coronary artery disease on baseline oral antiplatelets was associated with rapid onset, long-lasting, and dose-dependent P2Y12 inhibition, significantly increased compared to placebo [143].